TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ImmuPharma ( (GB:IMM) ) has issued an announcement.
ImmuPharma PLC has announced an update on its partnership discussions for P140, a promising autoimmune therapy. The company is engaging with several potential partners, including top global pharmaceutical companies, to secure a deal that aligns with its strategic goals. Although initially aiming for a deal by the end of 2025, the timeline has been extended into 2026 to ensure the best possible outcome for shareholders. Financially, ImmuPharma remains strong, with a cash runway extending into Q4 2026, supported by recent R&D tax credits and other financial strategies. The company’s focus is on securing a partnership that matches its long-term vision and enhances its market position.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Their portfolio includes novel treatments for autoimmune diseases and anti-infectives.
Average Trading Volume: 12,016,321
Technical Sentiment Signal: Buy
Current Market Cap: £49.07M
See more data about IMM stock on TipRanks’ Stock Analysis page.